ClinicalTrials.gg

Program

ibrutinib

Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.

Furthest: phase 4, since Jun 14, 201774 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson364 open or runningphase 4since Jun 14, 2017May 14, 2012Dec 31, 2026phase 3 · NCT01804686
AbbVie341 open or runningphase 4since Jun 5, 2017Feb 20, 2009May 10, 2027phase 4 · NCT03229200
Novartis21 open or runningphase 2since May 21, 2019Mar 13, 2019Jun 30, 2027phase 2 · NCT03960840
BeOne Medicines10 open or runningphase 3since Feb 7, 2017Feb 7, 2017none ahead
Oncternal Therapeutics10 open or runningphase 3since Jun 9, 2022Jun 9, 2022none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Oct 9, 2012.

  1. Mar 6, 20182 phase 3 studiesJohnson & Johnson · NCT03462719, NCT03474679
  2. Dec 12, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeAbbVie · NCT03790332 · 59 enrolled · United States, Australia, Austria and more
  3. Mar 12, 2019Phase 2 study in LeukemiaAbbVie · NCT03873493 · 14 enrolled · United States, Australia, Austria and more
  4. Mar 13, 2019Novartis's first study: phase 1 study in Lymphoma, Large B-Cell, DiffuseNew to NovartisNovartis · NCT03876028 · 10 enrolled · United States
  5. May 21, 2019Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840 · 218 enrolled · United States, Australia, Austria and more
  6. Jul 31, 2019Phase 4 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04042376 · 17 enrolled · China
  7. Aug 19, 2019Phase 2 study in Waldenstrom MacroglobulinemiaJohnson & Johnson · NCT04062448 · 16 enrolled · Japan
  8. May 4, 2020Phase 2 study in COVID-19AbbVie · NCT04375397 · 46 enrolled · United States
  9. Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellAbbVie · NCT04477486 · 13 enrolled · Japan
  10. Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
  11. Jun 9, 2022Oncternal Therapeutics's first study: phase 3 study in Lymphoma, Mantle-CellNew to Oncternal TherapeuticsOncternal Therapeutics · NCT05431179
  12. Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellJohnson & Johnson · NCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
  13. Jul 19, 2023Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074 · 333 enrolled · United States, Canada, Czechia and more
  14. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteJohnson & Johnson · NCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT01804686
  2. May 10, 2027Primary completion: phase 4 study in Lymphoma, B-CellAbbVie · NCT03229200
  3. Jun 30, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNovartis · NCT03960840
  4. Dec 15, 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellJohnson & Johnson · NCT05963074

TargetBeta

BTK →read by rule
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJohnson & JohnsonJan 19, 2028120
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Czechia and more2Active, not recruitingJohnson & JohnsonDec 15, 2027333
NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more2CompletedJohnson & JohnsonDec 6, 202336
NCT05431179Lymphoma, Mantle-Cell3WithdrawnOncternal TherapeuticsNov 20260
NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan2CompletedAbbVieOct 9, 202520
NCT04477486Lymphoma, Mantle-Cell · Japan2CompletedAbbVieFeb 9, 202213
NCT04375397COVID-19 · United States2CompletedAbbVieMay 10, 202146
NCT04062448Waldenstrom Macroglobulinemia · Japan2CompletedJohnson & JohnsonAug 24, 202116
NCT04042376Waldenstrom Macroglobulinemia · China4CompletedJohnson & JohnsonMar 19, 202417
NCT03960840Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2Active, not recruitingNovartisJun 30, 2027218
NCT03876028Lymphoma, Large B-Cell, Diffuse · United States1TerminatedNovartisNov 1, 202110
NCT03873493Leukemia · United States, Australia, Austria and more2CompletedAbbVieNov 4, 202114
NCT03790332Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more2CompletedAbbVieOct 9, 202559
NCT03474679Graft vs Host Disease · Japan3CompletedJohnson & JohnsonNov 29, 202119
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more3Active, not recruitingJohnson & JohnsonFeb 26, 2021211
NCT03301207Leukemia, Lymphocytic, Chronic, B-Cell · Poland, Spain1CompletedJohnson & JohnsonJul 17, 201825
NCT03190330Leukemia, Lymphocytic, Chronic, B-Cell · India4CompletedJohnson & JohnsonMay 3, 202375
NCT03229200Lymphoma, B-Cell · United States, Australia, Canada and more4Active, not recruitingAbbVieMay 10, 2027297
NCT03053440Waldenstrom Macroglobulinemia · United States, Australia, Czechia and more3CompletedBeOne MedicinesJun 21, 2022201
NCT02947347Lymphoma, Follicular · United States, Australia, Austria and more3CompletedAbbVieFeb 21, 2024445
NCT02959944Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more3CompletedAbbVieMar 27, 2020193
NCT02910583Leukemia · United States, Australia, Italy and more2CompletedAbbVieNov 12, 2020323
NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more2CompletedAbbVieOct 26, 201874
NCT02877225Healthy · United States1CompletedJohnson & JohnsonNov 11, 2016103
NCT02841150Healthy · United States1CompletedJohnson & JohnsonAug 2016102
NCT02703272Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more3TerminatedJohnson & JohnsonJun 11, 202172
NCT02638116Healthy · Belgium1CompletedJohnson & JohnsonMar 201620
NCT02599324Carcinoma, Renal Cell · United States, Korea, Republic of, Spain and more2CompletedAbbVieAug 20, 2021263
NCT02548962Multiple Myeloma · United States, Australia, Czechia and more2TerminatedAbbVieJun 13, 201811
NCT02556892Leukemia, Lymphoid · Japan1CompletedJohnson & JohnsonAug 20, 20188
NCT02436668Metastatic Pancreatic Adenocarcinoma · United States, Belgium, France and more3CompletedAbbVieOct 2018430
NCT02390609Healthy · Belgium1CompletedJohnson & JohnsonNov 201540
NCT02381080Leukemia, Lymphocytic, Chronic, B-Cell · Canada, Russian Federation, Spain1CompletedJohnson & JohnsonJun 24, 201626
NCT02351037Leukemia, Myeloid, Acute · United States2TerminatedAbbVieApr 201736
NCT02329847Hematologic Neoplasms · United States, Australia, Israel and more2CompletedJohnson & JohnsonFeb 9, 2022144
NCT02271438Healthy · Belgium1CompletedJohnson & JohnsonApr 201528
NCT02264574Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedAbbVieMar 26, 2018229
NCT02195869Graft vs Host Disease · United States2CompletedAbbVieSep 15, 201745
NCT02169180Lymphoma, Mantle-Cell · Japan2CompletedJohnson & JohnsonNov 201616
NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more3CompletedAbbVieNov 7, 2019181
NCT02142049Lymphoma · United States2CompletedAbbVieAug 201735
NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more2CompletedAbbVieDec 17, 2020138
NCT01980628Lymphoma, B-Cell, Marginal Zone · United States, Belgium, France and more2CompletedAbbVieJul 201663
NCT01974440Lymphoma · United States, Argentina, Australia and more3CompletedJohnson & JohnsonMay 30, 2022403
NCT01973387Leukemia, Lymphocytic, Chronic, B-Cell · Australia, China, Malaysia and more3CompletedJohnson & JohnsonDec 1, 2015160
NCT01980654Lymphoma, Follicular · United States2CompletedAbbVieNov 201780
NCT01962792Multiple Myeloma · United States, Canada2CompletedAbbVieMar 201984
NCT01969266Healthy Volunteer · United States1CompletedJohnson & JohnsonNov 20138
NCT01866033Healthy Volunteer · Belgium1CompletedJohnson & JohnsonAug 20138
NCT01855750Lymphoma · United States, Argentina, Australia and more3CompletedJohnson & JohnsonFeb 26, 2018838
NCT01820936Healthy Volunteers · United States1CompletedJohnson & JohnsonJun 201352
NCT01804686Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonDec 31, 2026539
NCT01779791Lymphoma · United States, Australia, Belgium and more2CompletedJohnson & JohnsonMay 18, 2016110
NCT01776840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more3CompletedJohnson & JohnsonJun 30, 2021523
NCT01767948Hepatic Impairment · United States1CompletedJohnson & JohnsonNov 201330
NCT01763021Healthy Participants · United States1CompletedJohnson & JohnsonJan 201318
NCT01744691Chronic Lymphocytic Leukemia With 17p Deletion · United States, Australia, Belgium and more2CompletedAbbVieJun 2014145
NCT01724346Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedAbbVieAug 18, 2023269
NCT01722487Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedAbbVieMay 2015269
NCT01704963Neoplasms · Japan1CompletedJohnson & JohnsonNov 20, 201515

How it is read

Names in the registry

  • “Ibrutinib”, 49 entries
  • “PCI-32765”, 10 entries
  • “ibrutinib”, 6 entries
  • “PCI-32765 (Ibrutinib)”, 2 entries
  • “SNX-5422 plus ibrutinib”, 2 entries

Codes read as this program: PCI32765.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.